心肌梗塞后伤害最小化:专注于细胞外囊泡
Lucio Barile1,2, Eduardo Marbán3
1Cardiovascular Theranostics, Istituto Cardiocentro Ticino, Laboratories for Translational Research, Ente Ospedaliero Cantonale, CH-6500, Bellinzona, Switzerland.
European heart journal
|February 17, 2024
概括
细胞外囊泡 (EVs) 显示为心脏病发作后心脏保护疗法的前景,与传统细胞治疗相比,具有优势. 大型动物研究和早期临床试验表明,电动汽车是改善心脏功能的可行,潜在的现成选择.
科学领域:
- 再生医学是一种再生医学.
- 心血管生物学 心血管生物学
- 生物技术是生物技术.
背景情况:
- 急性心肌梗塞 (AMI) 的死亡率仍然很高,特别是在低左心室喷射率 (LVEF) 的患者中.
- 现有的用于心脏修复的细胞疗法表现出有限的成功,需要新的心脏保护策略.
- 细胞外囊泡 (EVs) 正在成为心血管疾病的有前途的细胞模仿疗法.
研究的目的:
- 审查基于细胞外囊泡 (EV) 的治疗方法在心肌梗塞后的心脏保护的转化潜力.
- 突出大型动物研究的发现,评估EV的有效性和安全性.
- 总结正在进行的EV疗法在心脏病学的早期临床试验.
主要方法:
- 对临床前数据的审查,重点是心肌梗塞的大型动物模型.
- 分析EV的生物特性,包括它们的载荷和膜机制.
- 目前临床试验场景的概要,以EV为基础的心脏治疗.
主要成果:
- 源自介质细胞和心脏 stromal 先生细胞的 EVs 在临床前环境中证明了安全性和有效性.
- 电动疗法比细胞疗法具有临床优势,包括稳定性,储存潜力和降低免疫性.
- 大型动物研究支持EVs在心脏病发作后心脏修复方面的治疗潜力.
结论:
- 基于EV的疗法代表了再生医学在治疗心肌梗塞方面的有希望的进步.
- 电动汽车的独特特性有助于其发展成为"现成"的治疗产品.
- 目前正在进行的临床试验对于验证EV治疗在人类患者中的有效性和安全性至关重要.
更多相关视频
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.5K
05:30Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
Published on: January 31, 2025
406
相关概念视频
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...